FDA approves Teva's Igalmi for at-home treatment of acute agitation in adults with schizophrenia or bipolar disorder

The FDA has expanded the authorised use of Teva's Igalmi sublingual film to at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder and bipolar disorder, introducing a new outpatient treatment setting.
Teva announced on 16 November 2026 that the US Food and Drug Administration had approved Igalmi (dexmedetomidine) sublingual film for at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder and bipolar I or II disorder in adults, extending the medicine's use beyond healthcare-supervised administration.
The approval was supported by the Phase III SERENITY At-Home safety and tolerability study, which evaluated 1160 treated agitation episodes in 102 patients, and follows Teva's October 2026 acquisition of the Igalmi assets from BioXcel Therapeutics; the decision concerns a new setting of care for an existing medicine, with commercialisation plans not yet announced.
Field | Content |
Article Type | Approvals |
Company | Teva |
Product Brand Name | Igalmi |
Active Ingredient | Dexmedetomidine |
Dosage Form | Sublingual film |
Regulatory Authority | US Food and Drug Administration |
Approval Date | 16 November 2026 |
Regulatory Decision | Expanded authorised setting of care |
Geographic Scope | United States |
New Treatment Setting | At-home administration |
Previous Treatment Setting | Healthcare-supervised administration |
Therapeutic Area | Psychiatry |
Treatment Purpose | Acute agitation |
Approved Population | Adults with agitation associated with specified psychiatric disorders |
Indication One | Schizophrenia |
Indication Two | Schizoaffective disorder |
Indication Three | Bipolar I disorder |
Indication Four | Bipolar II disorder |
Supporting Clinical Trial | SERENITY At-Home |
Clinical Trial Phase | Phase III |
Trial Focus | Safety and tolerability of at-home treatment |
Treated Agitation Episodes | 1160 |
Study Participants | 102 |
Original Asset Developer | BioXcel Therapeutics |
Asset Acquirer | Teva |
Asset Acquisition Date | October 2026 |
First FDA-Approved At-Home Treatment Claim | First at-home treatment for agitation associated with the specified conditions according to supplied summary |
New Active Ingredient Approval | No |
Commercialisation Plans | Not yet announced according to supplied summary |
What Happened | The FDA authorised Igalmi for at-home management of acute agitation in adults with specified psychiatric conditions. |
Why It Matters | The approval introduces an additional treatment setting that may reduce reliance on healthcare facilities for eligible agitation episodes. |
Clinical Significance | The supporting study evaluated safety and tolerability across more than one thousand treated agitation episodes. |
Regulatory Significance | Expands an existing medicine's approved use from supervised administration to the home setting. |
Strategic Significance | Creates a new potential commercial opportunity for Teva following its acquisition of the Igalmi assets. |
Regulatory Clarification | This is a setting-of-care expansion rather than approval of a new molecular entity. |
Key Takeaway | Igalmi is now FDA-approved for at-home treatment of acute agitation associated with specified psychiatric disorders in adults. |
What to Watch | Prescribing guidance, patient and caregiver training, commercial launch plans, real-world safety and treatment adoption. |
Primary Source | Teva |
Primary Source URL | https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/U-S--FDA-Approves-IGALMI-as-First-At-Home-Acute-Treatment-for-Agitation-Associated-with-Schizophrenia-Schizoaffective-Disorder-or-Bipolar-I-or-II-Disorder-in-Adults/default.aspx |
Relevant Date | 16 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments